Skip to main content
HQHTekla Healthcare InvestorsHold5.5·$20.93
HoldModerate Confidence
Investment thesis

Despite an attractive valuation with a stated 71% margin of safety and volume accumulation signals, severe revenue deterioration of 42% year-over-year and a Piotroski F-Score of 2 out of 9 raise significant value-trap concerns; with price sitting less than 0.5% below near-term resistance and an unfavorable risk/reward of roughly 0.09-to-1, the setup offers no compelling entry.

Thesis pillars

  • Valuation Vs Value Trap Risk→Stable
  • Weak Financial Health Piotroski→Stable
  • Technical Accumulation Above 200ma↑Improving
  • +1 more pillar — see the Why tab for full reasoning

Pillars as of Jul 3, 2026

Full reasoning →

Open full analysis

Tekla Healthcare Investors (HQH) Stock Analysis

Inst Constrain edge

HoldVALUE-TRAP 2/5ValueShortModerate Confidence

Financial Services · Asset Management

Hold if already holding. Not a fresh buy at $20.93, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.1); Weak growth.

Abrdn Healthcare Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector, including the biotechnology, medical... Read more

$20.93+15.0% A.UpsideScore 5.5/10#123 of 229 Asset Management
QualityF-score2 / 9FCF yield—
IncomeYield11.80%(5y avg 10.67%)Payout50.34%sustainable
Stop $19.81Default target $24.07A.R:R 0.0:1

Hold if already holding. Not a fresh buy at $20.93, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.1); Weak growth. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 5.5/10, moderate confidence.

Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.

Thesis

Rewards
Sector modifier (Financial Services): +1.0
Attractive valuation
Margin of safety: 61%
Risks
V7 low-quality RISK_OFF penalty: -0.5 (Q=5.1)
Weak growth
Value-trap signals (2/5): Revenue declining (-42.1% YoY), Margin compression (op margin -125.5%)

Key Metrics

P/E (TTM)4.7
P/E (Fwd)—
Mkt Cap$1.2B
EV/EBITDA—
Profit Mgn4561.3%
ROE24.2%
Rev Growth-42.1%
Beta0.75
Dividend11.80%
Rating analysts—

Quality Signals

Piotroski F2/9MoatNarrow

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Revenue shrinking — -42.1% YoY. Growth thesis broken unless recovery story develops.static

Revenue Growth
0.0
Declining revenue: -42%
Low model confidence on this dimension (33%).

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Support Resistance
0.3
Bollinger
0.4
52w Position
7.3
GatesA.R:R UPSIDE_EXHAUSTED (upside=0.0%)Momentum 6.5>=5.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY NO DATESEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
70 · Overbought
↑ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $18.82Resistance $21.00

Price Targets

$20
$24
A.R:R0.0:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeRisk-Off

Analyst Consensus

Analysts0
Consensus—
Avg Target—

Earnings

We could not retrieve earnings history for HQH.
The company may be recently listed, pre-revenue, or its beat/miss record wasn't available from our source this run. Earnings signals feed the Growth and Catalyst score dimensions — absence here doesn't affect other dimensions.

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is HQH stock a buy right now?

Hold if already holding. Not a fresh buy at $20.93, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.1); Weak growth. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Default target $24.07 (+15.0%), stop $19.81 (−5.7%), A.R:R 0.0:1. Score 5.5/10, moderate confidence.

What is the HQH stock price target?

Default target: $24.07 (+15.0% upside). Default target $24.07 (+15.0%), stop $19.81 (−5.7%), A.R:R 0.0:1. Stop-loss: $19.81.

What are the risks of investing in HQH?

V7 low-quality RISK_OFF penalty: -0.5 (Q=5.1); Weak growth; Value-trap signals (2/5): Revenue declining (-42.1% YoY), Margin compression (op margin -125.5%).

Is HQH overvalued or undervalued?

Tekla Healthcare Investors trades at a P/E of 4.7 (forward N/A). TrendMatrix value score: 10.0/10. Verdict: Hold.

0
What does Tekla Healthcare Investors do?Abrdn Healthcare Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in...

Abrdn Healthcare Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector, including the biotechnology, medical devices, and pharmaceuticals industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as current or anticipated market position for services or products, experienced business management, recognized technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index, the S&P 500 Index, and the S&P 1500 Healthcare Index. Abrdn Healthcare Investors was formed on October 31, 1986 and is domiciled in the United States.

Related stocks: GAB (Gabelli Equity Trust, Inc. (The) · HLNE (Hamilton Lane Incorporated) · CII (BlackRock Enhanced Large Cap Co) · TWN (Taiwan Fund, Inc. (The)) · FFA (First Trust Enhanced Equity Inc)
Home › Stocks › HQH

Latest news

No recent news